Objective To investigate the efficacy of laparoscopic surgery combined with ginsenoside Rg3 on ovarian endomethosis and its side effcts. Methods One-hundred and eighteen pa0tients undergoing conservative laparoscopic surgery of ovarian endometriosis were randomly divided into three groups: ginsenoside Rg3 treatment group (n=39), gestrinone treatrnent group (n=41) and control group (n=38). All cases were followed up for 6～9 months. In addition, the recurrence rate and occurrence rate of side effects were compared across the three groups after surgery. Results There was no statistical difference across the three groups at 3 months after surgery. After drug withdrawal for 6 months, the recurrence rate was 3％ in ginsenoside Rg3 treatment group, 5％ in gestrinone treatment group and 22％ in the control group. Ginsenoside Rg3 treatment group had no significant difference in reoccurrenee rate with gestrinone treatment group but with the control group. Furthermore, statistical difference was found in side effects between ginsenoside Rg3 treatment and control groups. Conclusion Laparoscopic surgery combined with ginsenoside Rg3 treatment may help decrease the recurrence rate in treatment of ovarian endometriosis, with less side effects. This has proved that ginsenoside Rg3 as a new drug for treatment of ovarian endometriosis can be promoted in clinic.%目的 探讨腹腔镜手术联合人参皂苷Rg3治疗卵巢子宫内膜异位囊肿术后的疗效及不良反应.方法 选取卵巢子宫内膜异位症腹腔镜保守性手术患者118 例,分3组.人参皂苷Rg3组:人参皂苷Rg3治疗卵巢子宫内膜异位囊肿腹腔镜术后患者39例;孕三烯酮组:孕三烯酮治疗子宫内膜异位囊肿腹腔镜术后患者41例;空白对照组:单纯行腹腔镜手术患者38例.所有病例随访 6～9个月,并对比3组术后复发率及不良反应的发生率.结果 术后3个月,3组复发率比较差异无统计学意义.停药6个月,人参皂苷Rg3治疗组复发率为 3%,孕三烯酮治疗组治疗组复发率5%,单纯腹腔镜组治疗组复发率为 22%,人参皂苷Rg3组与孕三烯酮治疗组复发率比较差异无统计学意义,人参皂苷Rg3组与空白对照组比较差异有统计学意义.人参皂苷Rg3组与孕三烯酮组不良反应比较有统计学意义.结论 腹腔镜手术术后联合人参皂苷Rg3治疗子宫内膜异位症可以降低复发率,且不良反应少,证明人参皂苷Rg3作为治疗子宫内膜异位症的一种新药可在临床上推广.
展开▼
